505
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron

, , , , , & show all
Pages 866-876 | Accepted 01 May 2013, Published online: 20 May 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jyotsna Jayarajan & Sidney B Radomski. (2014) Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Research and Reports in Urology 6, pages 1-16.
Read now

Articles from other publishers (7)

Fitsum Sebsibe Teni, Ola Rolfson, Nancy Devlin, David Parkin, Emma Nauclér & Kristina Burström. (2022) Longitudinal study of patients’ health-related quality of life using EQ-5D-3L in 11 Swedish National Quality Registers. BMJ Open 12:1, pages e048176.
Crossref
Apostolos Apostolidis, Garyfalia Petoumenou & Manto Tzanetakou. (2020) Improvement of health-related quality of life in patients with overactive bladder syndrome: A subanalysis of the prospective, noninterventional study BELIEVE in the Greek population. Hellenic Urology 32:4, pages 135.
Crossref
Päivi Rahkola-Soisalo, Marcin BalcerzakJarno RuotsalainenTomi S. Mikkola. (2019) Patient utilization survey of mirabegron prescribed for overactive bladder. Investigative and Clinical Urology 60:2, pages 114.
Crossref
Mike Herdman, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui, Moses Huang, Marco Pavesi, Scott MacDiarmid, Marcus J. Drake & Nancy Devlin. (2017) Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial. The Patient - Patient-Centered Outcomes Research.
Crossref
Zalmai Hakimi, Mike Herdman, Marco Pavesi, Nancy Devlin, Jameel Nazir, Chris Hoyle & Isaac A. O. Odeyemi. (2016) Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Quality of Life Research 26:5, pages 1187-1195.
Crossref
Vik Khullar, Gerard Amarenco, Javier C. Angulo, Mary Beth Blauwet, Jameel Nazir, Isaac A. Odeyemi & Zalmai Hakimi. (2015) Patient‐reported outcomes with the β 3 ‐adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder . Neurourology and Urodynamics 35:8, pages 987-994.
Crossref
D. Castro-Diaz, C. R. Chapple, Z. Hakimi, M. B. Blauwet, L. Delgado-Herrera, W. Lau & S. Mujais. (2015) The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials. Quality of Life Research 24:7, pages 1719-1727.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.